Expert Opinion on Biological Therapy

Article	Citations
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	116
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	63
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	55
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	54
Aflibercept biosimilars – so near, yet so far	52
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	52
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	48
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	41
Antibody drug conjugates for glioblastoma: current progress towards clinical use	38
Biosimilars and access to biologic therapy in immune-mediated diseases	37
The endosomal-lysosomal system in ADC design and cancer therapy	33
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	33
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	28
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	27
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	26
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	26
Correction	24
Long-acting delivery and therapies for neovascular age-related macular degeneration	24
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	23
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	23
Signaling new therapeutic opportunities: cytokines in prostate cancer	22
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	21
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	20
Moving toward personalized approaches in the management of lupus nephritis	20
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	19

Correction	19
Correction	19
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	18
Strategies for extending the half-life of biotherapeutics: successes and complications	18
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	18
Unmet needs in cervical cancer – can biological therapies plug the gap?	18
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	18
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	18
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	18
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	17
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	16
Management of proctitis in ulcerative colitis and the place of biological therapies	16
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	16
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	16
Dynamics of biological markets with multiple biosimilar competitors in the United States	16
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	16
The nail in psoriatic arthritis: new insights into prognosis and treatment	16
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	16
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	15
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	15
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	15
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	15
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	15
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	15
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	14
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	14
Biological agents targeting interleukin-13 for atopic dermatitis	14
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	13
Recent advances in delivering RNA-based therapeutics to mitochondria	13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	13
Emerging peptide-based technology for biofilm control	13
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	13
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	13
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	13
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	12
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	12
An evaluation of pozelimab for the treatment of CHAPLE disease	12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	12
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	12
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	12
Treating psoriasis in the elderly: biologics and small molecules	11
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	11
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	11
Clinical management and innovation in fracture non-union	11

Tremelimumab for the treatment of hepatocellular carcinoma	11
Belimumab patient profile in Spain: evolution during the last decade and future directions	11
Biosimilars in osteoporosis treatment: focus on denosumab	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
Non-traditional approaches for control of antibiotic resistance	11
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	10
Prostate cancer immunotherapy	10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	10
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	10
Correction	10
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	10
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	10
X-linked myotubular myopathy: an untreated treatable disease	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
Sargramostim in acute radiation syndrome	10
Epcoritamab in B-cell malignancies: current status and prospects	10
Antibody therapeutics for epithelial ovarian cancer	10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	10
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	9
Rilonacept for the treatment of recurrent pericarditis	9
Hemophilia A gene therapy: current and next-generation approaches	9
Biologics in rectal cancer	9
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	9
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	9
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	9
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	9
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy	9
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	9
Ravulizumab for the treatment of myasthenia gravis	9
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	9
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	8
Belantamab mafodotin in multiple myeloma	8
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	8
The future of interleukin gene therapy in head and neck cancers	8
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	8
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	8
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	8
CAR T cells for solid tumors – developments to watch in 2023	8
The future of cellular therapy for the treatment of renal cell carcinoma	8
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	8
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast	7
The future of cancer vaccines against colorectal cancer	7
Non-TNF biologics and their biosimilars in rheumatoid arthritis	7
Gene therapy for choroideremia: progress, potential and pitfalls	7
The future of aptamers in cancer diagnosis, prognosis and treatment	7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	7
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	7
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	7
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross-sectional infodemiology study	7
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	7
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	7
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	7
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	7
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	6
Pathogenesis-oriented therapy of psoriasis using biologics	6
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	6
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	6
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	6
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	6
Immune checkpoint inhibitors for the treatment of melanoma	6
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	6

Perceptions of airway gene therapy for cystic fibrosis	6
Could siRNA therapeutics change the way we treat dyslipidemia?	6
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	6
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach	6
Correction	6
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	6
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	6
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting	6
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma	6
Current and preclinical treatment options for Merkel cell carcinoma	6
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	6
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	6
Elotuzumab in multiple myeloma	6
Therapeutic monoclonal antibodies for COVID-19 management: an update	6
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	6
Biological therapies in patients with liver disease: are they really lifesavers?	6
Hypoxic storage of red blood cells to improve transfusion outcomes in hematological malignancies	6
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	6
Recent developments in CD19-targeted therapies for follicular lymphoma	5
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	5
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	5
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	5
The evolving therapeutic landscape of diabetic retinopathy	5
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	5
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	5
Bintrafusp alfa and its unsuccessful development journey towards cervical cancer treatment	5
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	5
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	5
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer	5
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	5
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects	5
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	5
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	5
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	5
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	5
Biologics for dengue prevention: up-to-date	5
How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study	5
Oncolytic virus therapy for malignant gliomas: entering the new era	5
Targeting cervical cancer with anti-PD-1 antibodies: what is new?	4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2	4
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics	4
Addressing practical challenges with bispecific antibody therapy in multiple myeloma	4
Optimizing the use of vilobelimab for the treatment of COVID-19	4
Monoclonal antibodies as adjuvant therapies for resected melanoma	4
Biological therapies for myasthenia gravis	4
The cell replacement therapeutic potential of human pluripotent stem cells	4
Short and long-term economic implications of biosimilars	4
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement	4
An evaluation of nipocalimab for the treatment of generalized myasthenia gravis	4
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?	4
Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia	4
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development	4
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment	4
Correction	4
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance	4
Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review	4
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors	4
ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?	4
Sarilumab in the treatment of rheumatoid arthritis: future perspectives	4
Perispinal etanercept stroke trial design: PESTO and beyond	4
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	4
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch	4
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities	4
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence	4
Clinical advances in biological therapy for generalized pustular psoriasis: a review	4
Tight competition for the first-line treatment of Hodgkin’s lymphoma: a comprehensive review of practice-changing developments in recent years	3
Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments’ evidence: a systematic review an	3
Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management	3
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participant	3
Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM ): a multidisciplinary perspective	3
Biological therapies for the treatment of psoriasis in pediatrics	3
Biological therapy in elderly patients with acute myeloid leukemia	3
What is ‘ chronic ’ pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment	3
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	3
What role can LAG-3-blocking antibodies play in melanoma therapy?	3
An evaluation of bimekizumab for the treatment of hidradenitis suppurativa	3
Adjuvant immunotherapy for locally advanced renal cell carcinoma	3
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies	3
Advances in biological and targeted therapies for systemic sclerosis	3
Chasing optimal first-in-human (FIH) starting dose for biotherapeutics in oncology	3
Oncolytic adenoviruses in platinum-resistant ovarian cancer: a new era in immunotherapy?	3
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	3
Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies	3
Biologics for psoriasis: is there any unmet need left?	3
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	3
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	3
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network	3
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian valore distributed database network	3
Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis	3
Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States	3
Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan	3
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use	3
A plain language summary of the pooled safety results of adalimumab-adbm from the VOLTAIRE clinical trials in people with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	3
Management of metastatic melanoma with combinations including PD-1 inhibitors	3
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	3